DEPRECAP: Lung Cancer Screening Programme by LDCT for Patients With COPD or Emphysema.

Phase

N/A

Condition

Non-small Cell Lung Cancer

Lung Cancer

Lung Disease

Treatment

N/A

Clinical Study ID

NCT06690385

ER2_EO180-19_FJD-HGV

Ages 55-75
All Genders

Study Summary

The DEPRECAP (Early detection of lung cancer) study is an ongoing, prospective, longitudinal, multicenter lung cancer screening program that recruited individuals with COPD or emphysema from the pulmonary clinics of Fundación Jiménez Díaz University Hospital and Villalba General Hospital, in Madrid, Spain.

The aim of this observational study is to determine the scientific evidence needed to study the benefit and potential effects of lung cancer screening in this group of patients and to determine the long-term effects of the intervention in reducing the high mortality rates associated with late-stage lung cancer diagnosis in a very high-risk population, to address under-diagnosis of COPD and to promote smoking cessation. This leads to the creation of a registry with clinical, radiological, functional data and biological samples for future studies in this cohort of patients to provide the scientific evidence needed to study the benefit and potential effects of screening for lung cancer and other tobacco-related pathologies diagnosed by Low-dose CT (LDCT)

Eligibility Criteria

Inclusion

Inclusion Criteria:

Current or former smokers (>15 years of abstinence) with a cumulative smokingexposure of > 30 pack-years
Diagnosis of COPD according to the GOLD guidelines and/or emphysema identified byLDCT and/or a carbon monoxide diffusing capacity (DLCO) lower than 80% of predicted (as per the Global Lung Function Initiative (GLI) equations)

Exclusion

Exclusion Criteria:

Individuals with a recent history of cancer (except non-melanoma skin cancer orcarcinoma in situ) as well as those with other medical conditions that posed asignificant risk of death were excluded from the study.

Study Design

January 14, 2014

November 13, 2024

Study Description

Participants who met the inclusion/exclusion criteria detailed below and agreed to participate, underwent annual LDCT and pulmonary function tests until age 75 or 15 years of smoking abstinence, whichever came first. The study protocol was approved by the Ethics Committee of the Fundación Jiménez Díaz (ER2_EO180-19_FJD-HGV) and all participants signed their informed consent.

Inclusion criteria were males or females, 55-75 years of age, current or former smokers (Less than 15 years of abstinence) with a cumulative smoking exposure of greather than 30 pack-years and a diagnosis of COPD according to the GOLD guidelines and/or emphysema identified by LDCT. Individuals with a recent history of cancer (except non-melanoma skin cancer or carcinoma in situ) as well as those with other medical conditions that posed a significant risk of death were excluded.

Connect with a study center

Fundación Jimenez Díaz Universitary Hospital
Madrid, 28040
Spain
Active - Recruiting
Pneumology department. Fundación Jimenez Díaz University Hospital
Madrid, 28040
Spain
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.